The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...

Esketamine targets the glutamate neurotransmitter pathway, offering a novel mechanism for treatment-resistant depression. The treatment is available through a Risk Evaluation and Mitigation ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & ...